24/7 Market News – (NYSE: RMED) Ra Medical Systems, Inc. Shares are Surging More than 55% in Pre-Market Trading this Morning at .49.

The Company Announced FDA 510K Approval of their Catheter Product. Shares are up on more than 13,000 trades and 11 million in volume. The company has traded more than 90 million shares back in March of this year, and saw the stock trade just below a dollar.

(24/7 MARKET NEWS) — Ra Medical Systems, Inc. (NYSE: RMED) is trading higher after announcing, this morning, that it received FDA 510(k) clearance for the Company’s DABRA 2.0 catheter as part of the DABRA Excimer Laser System. RA Medical shares are at $0.500, up $0.191 (+61.88%), on 7.83million shares.

24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

Ra Medical Systems Receives FDA 510(k) Clearance for the DABRA 2.0 Catheter

Board of Directors continues its review of strategic alternatives to determine the Company’s optimal path forward

https://www.businesswire.com/news/home/20220705005320/en/Ra-Medical-Systems-Receives-FDA-510-k-Clearance-for-the-DABRA-2.0-Catheter

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED)(“Ra Medical” or the “Company”), a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces receipt of U.S. Food and Drug Administration 510(k) clearance for the Company’s DABRA 2.0 catheter as part of the DABRA Excimer Laser System. This next-generation DABRA catheter features enhancements including a braided overjacket design that’s intended to improve deliverability and kink resistance when navigating tortuous anatomy, as well as a six-month shelf life.

“As we have previously announced, the DABRA 2.0 catheter represents an interim step in our work to develop a guidewire-compatible version of the DABRA catheter, and at this time we have no plans to commercialize the DABRA 2.0.”Tweet this